Nextgen (NXGN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Nextgen (NXGN) has a cash flow conversion efficiency ratio of 0.111x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (ILA-1.08 Million ≈ $-2.90K USD) by net assets (ILA-9.72 Million ≈ $-26.05K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of Nextgen to measure how much of total assets are equity-financed.
Nextgen - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Nextgen's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore NXGN operating cash flow to total debt to assess how comfortably operating cash covers total debt obligations.
Nextgen Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Nextgen ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
MUZHU MINING LTD
F:Y33
|
N/A |
|
Severfield PLC
LSE:SFR
|
0.125x |
|
Rights and Issues Investment Trust Public Limited Company
LSE:RIII
|
0.012x |
|
Grupo Vasconia S.A.B
MX:VASCONI
|
0.006x |
|
Margaret Lake Diamonds Inc
V:DIA
|
0.054x |
|
Future Supply Chain Solutions Limited
NSE:FSC
|
0.108x |
|
Diaceutics PLC
LSE:DXRX
|
0.021x |
|
Ucommune International Ltd
NASDAQ:UK
|
-0.019x |
Annual Cash Flow Conversion Efficiency for Nextgen (2013–2024)
The table below shows the annual cash flow conversion efficiency of Nextgen from 2013 to 2024. For the full company profile with market capitalisation and key ratios, see NXGN market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ILA-2.46 Million ≈ $-6.61K |
ILA-2.06 Million ≈ $-5.53K |
0.837x | -81.41% |
| 2023-12-31 | ILA-979.00K ≈ $-2.62K |
ILA-4.41 Million ≈ $-11.81K |
4.499x | +2102.13% |
| 2022-12-31 | ILA12.25 Million ≈ $32.84K |
ILA-2.75 Million ≈ $-7.38K |
-0.225x | -75.07% |
| 2021-12-31 | ILA20.71 Million ≈ $55.51K |
ILA-2.66 Million ≈ $-7.13K |
-0.128x | +42.64% |
| 2020-12-31 | ILA6.87 Million ≈ $18.41K |
ILA-1.54 Million ≈ $-4.12K |
-0.224x | +77.11% |
| 2019-12-31 | ILA1.17 Million ≈ $3.14K |
ILA-1.15 Million ≈ $-3.07K |
-0.978x | -88.16% |
| 2018-12-31 | ILA2.39 Million ≈ $6.40K |
ILA-1.24 Million ≈ $-3.33K |
-0.520x | -14.45% |
| 2017-12-31 | ILA3.66 Million ≈ $9.81K |
ILA-1.66 Million ≈ $-4.45K |
-0.454x | -54.05% |
| 2016-12-31 | ILA5.13 Million ≈ $13.76K |
ILA-1.51 Million ≈ $-4.06K |
-0.295x | +87.25% |
| 2015-12-31 | ILA1.74 Million ≈ $4.65K |
ILA-4.01 Million ≈ $-10.76K |
-2.312x | -162.46% |
| 2014-12-31 | ILA-884.00K ≈ $-2.37K |
ILA-3.27 Million ≈ $-8.77K |
3.702x | +205.08% |
| 2013-12-31 | ILA342.00K ≈ $916.89 |
ILA-1.21 Million ≈ $-3.23K |
-3.523x | -- |
About Nextgen
Nextgen Biomed Ltd develops topical treatment for psoriasis. The company was formerly known as Sela Group.Com Ltd. and changed its name to Nextgen Biomed Ltd in February 2010. Nextgen Biomed Ltd was incorporated in 1990 and is based in Tel Aviv, Israel.